541
Participants
Start Date
January 31, 2003
Study Completion Date
June 30, 2004
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
Placebo
The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
New York
East Steauket
Arlington
Palm Springs
St. Petersburg
Venice
Mobile
Louisville
Fridley
Shawnee
Byran
Castle Rock
Denver
Boise
Kingman
Westlake Village
Encino
San Diego
San Diego
Medford
Seattle
Portland
Lead Sponsor
Bayer
INDUSTRY